Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 4/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | HCK | P08631 | 1/20 | 0.30 |
| ▸ | FGR | P09769 | 1/20 | 0.30 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.30 |
| ▸ | FLT4 | P35916 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.30 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.30 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909657 | 1.00 | CHRNB2 (0.32) | CHRNB2CHRNA5CHRNB4CHRNA3RET | |
| SCHEMBL3920096 | 0.91 | CHRNB2 (0.39) | CHRNB2CHRNA5CHRNB4CHRNA3RET | |
| SCHEMBL3920102 | 0.91 | CHRNB2 (0.39) | CHRNB2CHRNA5CHRNB4CHRNA3RET | |
| SCHEMBL4913152 | 0.85 | CHRNB2 (0.33) | CHRNB2CHRNA5CHRNB4CHRNA3RET | |
| SCHEMBL4916841 | 0.85 | CHRNB2 (0.33) | CHRNB2CHRNA5CHRNB4CHRNA3RET | |
| SCHEMBL4917368 | 0.82 | CHRNB2 (0.34) | CHRNB2CHRNA5CHRNB4CHRNA3RET | |
| SCHEMBL4920078 | 0.82 | CHRNB2 (0.34) | CHRNB2CHRNA5CHRNB4CHRNA3RET | |
| SCHEMBL4914568 | 0.82 | CHRNB4 (0.32) | CHRNB2CHRNA5CHRNB4CHRNA3RET | |
| SCHEMBL4920057 | 0.82 | CHRNB4 (0.32) | CHRNB2CHRNA5CHRNB4CHRNA3RET | |
| SCHEMBL4917757 | 0.80 | RET (0.34) | RETCYP1A2HCKFGRRPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161278-A1 | 2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity | ASTRAZENECA AB (SE) | 2008-07-03 | — | — | US | disclosed |
| EP-1863797-A1 | 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006100461-A1 | 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161278-A1 | 2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity | IGF1R, IGFBP1, IGFBP2 | CHRNB2 4588/4885CHRNA5 4478/4885CHRNB4 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.